Background:
- The mTOR pathway is a central signaling circuit in many tumors and contributes to cell growth•The phase III SUCCEED trial (2012) showed statistically significant—but clinically minimal—difference in PFS with the mTOR inhibitor (mTORi) ridaforolimus after chemo response, but didn’t stratify by molecular findings
- The AMPECT trial (2021) showed activity of nab-sirolimus in PEComa, especially in TSC2-mut tumors